Why the CRISPR patent verdict isn’t the end of the story – Nature.com
Nature.com |
Why the CRISPR patent verdict isn't the end of the story
Nature.com It ruled that the Broad Institute of Harvard and MIT in Cambridge could keep its patents on using CRISPR–Cas9 in eukaryotic cells. That was a blow to the University of California in Berkeley, which had filed its own patents and had hoped to have the … Who should be allowed to use CRISPR? UC Berkeley suffers big loss in CRISPR patent fight: What's next for the powerful gene-editing technology? CRISPR patent dispute ends well for Broad Institute. Berkeley says: Not so fast |
